Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
TORONTO, Jan. 17, 2022 (GLOBE...
Revive Therapeutics Updates, on Phase III Clinical Trial!
Michael Frank, CEO of the Company commented, "We are now in the final stages in our Phase 3 study.."
Revive Therapeutics Provides Update on...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
NEWS ARCHIVE INTRO
“These medicines have a sweet spot. If the day you get diagnosed with COVID you...
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as the rate...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here's...
Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.
Added to 12 Biotech Stocks we Expect to Double List.
The Original Biotech 6-Pack from 2020, is Growing to a 12-Pack!
Okay, here's our second...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
What Do We Have in April's Bag of Tricks?1. Revive Therapeutics (RVVTF) Moves a...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found in Virtually all...
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Provention Bio (PRVB) Updates.
RELATED: Revive Therapeutics (RVVTF) Enters the Danger Zone.
Provention Bio...
Latest article
Cabaletta (CABA) Surges 44% on Massive Volume Spike.
Biotech 12 Pack Off to Nice Start..
Cabaletta up 35%, GeoVax up 75%, and Replimune up 62%. All since late April!
Biotech Stock Review is...
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Wednesday afternoon, the 29th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
